LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

Search

Becton Dickinson and Co

Aperta

SettoreSettore sanitario

191.23 1.22

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

187.55

Massimo

192.06

Metriche Chiave

By Trading Economics

Entrata

222M

552M

Vendite

237M

5.5B

P/E

Media del settore

35.344

35.733

EPS

3.68

Rendimento da dividendi

2.13

Margine di Profitto

10.02

Dipendenti

70,000

EBITDA

927M

1.5B

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

-1.32% downside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

2.13%

3.13%

Utili prossimi

6 nov 2025

Prossima data del Dividendo

30 set 2025

Prossima data del' Ex Dividendo

8 dic 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

4B

55B

Apertura precedente

190.01

Chiusura precedente

191.23

Notizie sul Sentiment di mercato

By Acuity

50%

50%

173 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Becton Dickinson and Co Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 ago 2025, 11:19 UTC

Utili

Becton Dickinson Boosts Outlook as 3Q Results Beat Estimates

14 lug 2025, 14:26 UTC

Acquisizioni, Fusioni, Takeovers

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5 Billion Deal -- 2nd Update

14 lug 2025, 11:08 UTC

Acquisizioni, Fusioni, Takeovers

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal -- Update

14 lug 2025, 10:37 UTC

Acquisizioni, Fusioni, Takeovers

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal

7 ago 2025, 10:32 UTC

Utili

Becton Dickinson Expects to Complete Remaining $250M of $1B Share-Buyback Commitment by End FY25 >BDX

7 ago 2025, 10:31 UTC

Utili

Becton Dickinson Backs FY25 View of Rev $21.8B-$21.9B >BDX

7 ago 2025, 10:31 UTC

Utili

Becton Dickinson Had Seen FY25 Adjusted EPS $14.06-$14.34 >BDX

7 ago 2025, 10:30 UTC

Utili

Becton Dickinson Raises FY25 View To Adj EPS $14.30-Adj EPS $14.45 >BDX

7 ago 2025, 10:30 UTC

Utili

Becton Dickinson 3Q Adj EPS $3.68 >BDX

7 ago 2025, 10:30 UTC

Utili

Becton Dickinson 3Q Net $574M >BDX

7 ago 2025, 10:30 UTC

Utili

Becton Dickinson 3Q Rev $5.51B >BDX

7 ago 2025, 10:30 UTC

Utili

Becton Dickinson 3Q EPS $2.00 >BDX

15 lug 2025, 18:32 UTC

Acquisizioni, Fusioni, Takeovers

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15 lug 2025, 18:31 UTC

Acquisizioni, Fusioni, Takeovers

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

14 lug 2025, 16:12 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

14 lug 2025, 15:06 UTC

Acquisizioni, Fusioni, Takeovers

Waters Stock Is Falling on Deal to Combine With Becton Dickinson Unit -- Barrons.com

14 lug 2025, 14:11 UTC

Acquisizioni, Fusioni, Takeovers

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5B Deal -- 2nd Update

14 lug 2025, 10:53 UTC

Acquisizioni, Fusioni, Takeovers

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal -- Update

14 lug 2025, 10:22 UTC

Acquisizioni, Fusioni, Takeovers

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal

14 lug 2025, 10:22 UTC

Acquisizioni, Fusioni, Takeovers

Waters To Assume About $4 Billion Incremental Debt >WAT BDX

14 lug 2025, 10:22 UTC

Acquisizioni, Fusioni, Takeovers

Becton Dickinson to Get $4 Billion Cash Distribution Prior to Closing >WAT BDX

14 lug 2025, 10:21 UTC

Acquisizioni, Fusioni, Takeovers

Waters Holders to Own 60.8% of Combined Company, Becton Dickinson Holders to Own 39.2% >WAT BDX

14 lug 2025, 10:20 UTC

Acquisizioni, Fusioni, Takeovers

Waters, Becton Dickinson: Combined Company to Have About $9 Billion Revenue, $3.3 Billion Adjusted Ebitda >WAT

14 lug 2025, 10:19 UTC

Acquisizioni, Fusioni, Takeovers

Correct: Waters, Becton Dickinson See About $290 Million Revenue Synergies by Year Five >WAT BDX

14 lug 2025, 10:19 UTC

Acquisizioni, Fusioni, Takeovers

Waters, Becton Dickinson See About $345 Million Annualized Ebitda Synergies by 2030 >WAT BDX

14 lug 2025, 10:18 UTC

Acquisizioni, Fusioni, Takeovers

Waters, Becton Dickinson See About $290 Revenue Cost Synergies by Year Five >WAT BDX

14 lug 2025, 10:18 UTC

Acquisizioni, Fusioni, Takeovers

Waters, Becton Dickinson See About $200 Million Cost Synergies by Year Three >WAT BDX

14 lug 2025, 10:17 UTC

Acquisizioni, Fusioni, Takeovers

Waters: Becton Dickinson Deal Doubles Total Addressable Market to About $40 Billion >WAT

14 lug 2025, 10:16 UTC

Acquisizioni, Fusioni, Takeovers

Waters, Becton Dickinson Deal Structured as Reverse Morris Trust >WAT BDX

14 lug 2025, 10:16 UTC

Acquisizioni, Fusioni, Takeovers

Waters, Becton Dickinson Deal Valued at About $17.5 Billion >WAT BDX

Confronto tra pari

Modifica del prezzo

Becton Dickinson and Co Previsione

Obiettivo di Prezzo

By TipRanks

-1.32% in calo

Previsioni per 12 mesi

Media 189.86 USD  -1.32%

Alto 200 USD

Basso 183 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Becton Dickinson and Co - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

8 ratings

1

Acquista

7

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

167 / 206.99Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

173 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
help-icon Live chat